Drug intelligence / Profile preview

nafulizumab

Development stage: Unknown
Lead developer: Polpharma Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Nafulizumab is a monoclonal antibody that functions as an anti-PD-1/PD-L1 inhibitor. It is currently under investigation in clinical trials for various cancers, including advanced non-small cell lung cancer and relapsed and refractory cervical cancer. Its mechanism involves blocking the PD-1/PD-L1 signaling pathway, which is crucial for tumor immune escape, thereby enhancing the immune system's anti-tumor effect.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on nafulizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nafulizumab.

Explore the full profile